References
- Coghi P, Yang LJ, Ng JPL, Haynes RK, Memo M, Gianoncelli A, Wong VKW, Ribaudo G. 2021. A drug repurposing approach for antimalarials interfering with SARS-CoV-2 spike protein receptor binding domain (RBD) and human angiotensin-converting enzyme 2 (ACE2). Pharmaceuticals (Basel). 14(10):954.
- Coghi P, Yun XY, Ng JPL, Law BYK, Memo M, Gianoncelli A, Wong VKW, Ribaudo G. 2022. Exploring SARS-CoV-2 delta variant spike protein receptor-binding domain (RBD) as a target for tanshinones and antimalarials. Nat Prod Res. 36(23):6150–6155.
- Demeke CA, Woldeyohanins AE, Kifle ZD. 2021. Herbal medicine use for the management of COVID-19: a review article. Metabol Open. 12:100141.
- Goc A, Sumera W, Rath M, Niedzwiecki A. 2021. Phenolic compounds disrupt spike-mediated receptor-binding and entry of SARS-CoV-2 pseudo-virions. PLoS One. 16(6):e0253489.
- Jena AB, Kanungo N, Nayak V, Chainy GBN, Dandapat J. 2021. Catechin and curcumin interact with S protein of SARS-CoV2 and ACE2 of human cell membrane: insights from computational studies. Sci Rep. 11(1):8482.
- Komatsu H, Tanaka T, Ye Z, Ikeda K, Matsuzaki T, Yasugi M, Hosoda M. 2023. Identification of SARS-CoV-2 main protease inhibitors from FDA-approved drugs by artificial intelligence-supported activity prediction system. J Biomol Struct Dyn. 41(5):1767–1775.
- Malabadi RB, Meti NT, Chalannavar RK. 2021. Role of herbal medicine for controlling coronavirus (SARS-CoV-2) disease (COVID-19). Int J Res Sci Innov. 8(2):135–165.
- Marín-Palma D, Tabares-Guevara JH, Zapata-Cardona MI, Flórez-Álvarez L, Yepes LM, Rugeles MT, Zapata-Builes W, Hernandez JC, Taborda NA. 2021. Curcumin inhibits in vitro SARS-CoV-2 infection in Vero E6 cells through multiple antiviral mechanisms. Molecules. 26(22):6900.
- Nag A, Paul S, Banerjee R, Kundu R. 2021. In silico study of some selective phytochemicals against a hypothetical SARS-CoV-2 spike RBD using molecular docking tools. Comput Biol Med. 137:104818.
- Patel A, Rajendran M, Shah A, Patel H, Pakala SB, Karyala P. 2022. Virtual screening of curcumin and its analogues against the spike surface glycoprotein of SARS-CoV-2 and SARS-CoV. J Biomol Struct Dyn. 40(11):5138–5146.
- Rattis BAC, Ramos SG, Celes MRN. 2021. Curcumin as a potential treatment for COVID-19. Front Pharmacol. 12:675287.
- Ribaudo G, Coghi P, Yang LJ, Ng JPL, Mastinu A, Memo M, Wong VKW, Gianoncelli A. 2022. Computational and experimental insights on the interaction of artemisinin, dihydroartemisinin and chloroquine with SARS-CoV-2 spike protein receptor-binding domain (RBD). Nat Prod Res. 36(20):5358–5363.
- Shanmugarajan DPP, Kumar BRP, Suresh B. 2020. Curcumin to inhibit binding of spike glycoprotein to ACE2 receptors: computational modelling, simulations, and ADMET studies to explore curcuminoids against novel SARS-CoV-2 targets. RSC Adv. 10(52):31385–31399.
- Vahedian-Azimi A, Abbasifard M, Rahimi-Bashar F, Guest PC, Majeed M, Mohammadi A, Banach M, Jamialahmadi T, Sahebkar A. 2022. Effectiveness of curcumin on outcomes of hospitalized COVID-19 patients: a systematic review of clinical trials. Nutrients. 14(2):256.